Use of a Cancer Registry to Evaluate Patient-Reported Outcomes of Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) are increasingly used for advanced lung cancer, but few studies have reported on patient-reported outcomes (PROs) outside the context of a clinical trial. The goal of the current study was to assess PROs in patients participating in the GO(2) Found...

Descripción completa

Detalles Bibliográficos
Autores principales: Jim, Heather S. L., Eisel, Sarah L., Hoogland, Aasha I., Shaw, Sandra, King, Jennifer C., Dicker, Adam P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795027/
https://www.ncbi.nlm.nih.gov/pubmed/33396286
http://dx.doi.org/10.3390/cancers13010103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795027/
https://www.ncbi.nlm.nih.gov/pubmed/33396286
http://dx.doi.org/10.3390/cancers13010103

Ejemplares similares